Paolo Bongioanni, MD, PhD; Francesco Lombardo, MD; Gianluca Moscato, MD; Serena Mosti, MD; Giuseppe Meucci, MD
Arch Neurol 1999;56:217-222
To investigate the effects of Interferon-ß treatment on T-Cell Interferon binding (which is a possible marker for T-Cell-dependent Immune function) in patients with Multiple Sclerosis (MS).
Assay Interferon gamma binding on T-Lymphocytes from patients with stable Relapsing/Remitting MS before, 3 months after, and 6 months after initiating Interferon-ß-1b treatment.
The study was performed on ambulatory patients in a tertiary care center, where patients were diagnosed as having definite MS.
Eighteen patients with clinically definite, stable, Relapsing/Remitting MS (13 women and 5 men; mean age [± SD] 32.6 ± 7.1 years) were selected consecutively. Clinical status was defined according to the Kurtzke Expanded Disability Status Scale.
All patients were treated with 8 × 106 IU Interferon-ß-1b subcutaneously every other day. Eighteen age- and sex-matched healthy subjects with no family history of NeuroPsychiatric disorders formed the control group.
T-Lymphocytes from untreated patients with MS had significantly smaller amounts of Interferon- receptors than those from control subjects (638 ± 7 [SE] vs 707 ± 11 [SE] receptors per cell).
After 3 months of Interferon-ß-1b treatment, they showed a significant increase in Interferon binding (681 ± 9 [SE] receptors per cell). After 6 months, T-Cell Interferon maximal receptor values were even higher (700 ± 7 [SE] receptors per cell), only slightly lower than those of control subjects.
Given that reduced Interferon binding might be related to Lymphocytes activation, our data seem to demonstrate that the major effect of Interferon-ß-1b treatment is a decrease in T-Cell activation.